Practical demonstration of time bias with administration of adjuvant therapy in lung cancer

Neil B. Newman, Evan C. Osmundson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose/Background: Immortal time bias (ITB) can hinder appropriate interpretations of studies administering adjuvant therapies. Given the increase in National Cancer Data Base (NCDB) analyses evaluating postoperative radiation therapy (PORT) as an adjuvant therapy, we sought to practically demonstrate the effects of ITB by performing a series of simulated NCDB analyses. Methods: A simulated NCDB analysis was performed to examine how the reported benefit of PORT in stage III non-small cell lung cancer (NSCLC) may change with adjustment for ITB utilizing sequential land mark analysis (SLMA) and time dependent Cox (TDC) modeling. Results: On the simulation analysis of 6440 NSCLC patients, we found that the omission of PORT without ITB adjustment was associated with an increased risk of death (HR 1.17, p < 0.0001). After performing a sequential LMA, the detrmient of omitting PORT continued to decrease until it was no longer significant at 8 months, HR 1.05 (p = 0.09). With the TDC model, although still significant, the relative benefit of PORT decreased, to a HR of 1.07 (p = 0.02). Conclusions: Immortal time bias can alter the results of survival analyses if not carefully accounted for. Adjusting for this bias is essential for accurate data interpretation and to better quantify the impact and effect size of adjuvant therapies such as PORT.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
JournalLung Cancer
Volume157
DOIs
StatePublished - Jul 2021
Externally publishedYes

Keywords

  • Immortal time bias
  • Landmark analysis
  • National Cancer Data Base
  • Time dependent

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Practical demonstration of time bias with administration of adjuvant therapy in lung cancer'. Together they form a unique fingerprint.

Cite this